On Monday, Lennar Corporation (NYSE:LEN)’s shares inclined 0.72% to $47.81.
Lennar Corporation (LEN) declared that the Company will release earnings for the second quarter ended May 31, 2015 before the market opens on June 24, 2015. Additionally, the Company will hold a conference call on June 24, 2015 at 11:00 a.m. Eastern Time.
Lennar Corporation, together with its auxiliaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Homebuilding Southeast Florida, Homebuilding Houston, Financial Services, Rialto, and Lennar Multifamily segments. Its homebuilding activities primarily comprise the construction and sale of single-family attached and detached homes to first-time, move-up, and active adult homebuyers, in addition to the purchase, development, and sale of residential land.
Quantum Corp (NYSE:QTM)’s shares dropped -4.81% to $1.78.
Quantum Corp (QTM) has signed a definitive agreement (the “Agreement”) to acquire Columbus Hospital LTACH, LLC (the “LTACH”) http://columbusltach.org/, a company operating a long term acute care hospital in New Jersey (the “Acquisition”).
The LTACH is presently running on a four month unaudited annualized basis of about US$40,000,000 in revenue and about US$13,500,000 of EBITDA. QIIC’s legal counsel engaged independent consultants, Navigant Consulting Inc., to conduct a compliance review which has been accomplished. In addition, an independent external auditor was retained to conduct a financial review of the LTACH, which is ongoing.
Quantum Corporation provides scale-out storage, archive, and data protection solutions for small businesses to major enterprises in the Americas, Europe, and the Asia Pacific. Its scale-out storage and archive products comprise StorNext File System software, which provides file sharing, storage, and archive for content workflows, digital libraries, and data repositories; StorNext Storage Manager software that automatically copies and migrates data between different tiers of storage based on user-defined policies; StorNext appliances that offer predictable file sharing and in purpose-built configurations of metadata controllers, expansion appliances, and disk and archive enabled libraries; and Lattus Object Storage solutions, which enable high volumes of data to be accessible at any time to extract valuable information.
At the end of Monday’s trade, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s shares surged 2.47% to $173.22.
Traders are betting that Alexion Pharmaceuticals, Inc. (ALXN) will rally by the end of next week.
About 2,000 June 165 calls were purchased for $1.42 to $1.94 yesterday, according to optionMONSTER’s Heat Seeker tracking program. This represents fresh buying, as open interest in the strike was only 195 contracts before the session began.
These long calls lock in the price where investors can buy the stock through expiration in seven sessions, letting them position for a rally at limited cost. They carry less risk than owning shares because the most that can be lost is the price of the options no matter how far the stock might fall. (See our Education section)
The drug maker gapped down in early May on news that it would buy Synageva BioPharma. Shares rebounded but then lost those gains and have been trading sideways in an extremely tight range for the last week.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ended its Monday’s trading session with 2.92% gain, and closed at $4.23.
Arena Pharmaceuticals, Inc. (ARNA) declared that Steve Chalgren , Arena’s executive vice president of product administration and chief strategy officer, will speak at the CIMdata PLM Road Map conference for the High Tech Electronics Community, taking place June 16, 2015 at the Biltmore Hotel & Suites in Santa Clara, California .
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases. Its products under development comprise Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, counting potentially pulmonary arterial hypertension that is in Phase II clinical trials.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
